Healthcare is entering a defining moment, with an opportunity to embrace a new wave of innovation. Yet if Europe is to realise the full potential of these breakthroughs, it is vital that people across the region have more timely and equitable access to these treatments. It is with this potential in mind that I take up a new position on the Board of the European Federation of Pharmaceutical Industries and Associations (EFPIA) – the main body representing the research-based biopharmaceutical industry in Europe. Alongside my peers from world-leading pharmaceutical companies, I will be working to help deliver on EFPIA’s mission to create an environment that enables our industry to innovate, thrive and deliver new therapies across Europe. At Pfizer, our goal is to change the lives of one billion patients a year by 2027 – but as EFPIA’s mission alludes, this is only possible with the right policy and legislative environment in place. Europe is often seen as a pharmaceutical powerhouse, with the skilled workforce, academic infrastructure, multi-national institutions, and manufacturing capability making it a location of choice for life science investment. Yet in spite of all this expertise and promise there is still significant inequity in access to new medicines. Patients in Europe are having to wait 517 days for access to innovative treatments on average, ranging from 128 days up to a staggering 1,351 days.* This is an unacceptable situation, and I believe our industry is and should remain an important voice in profiling and remedying this issue. Timely and equitable access is a cause I am deeply passionate about. Through my new role on the EFPIA Board, I am committed to finding and fighting for solutions in partnership with policymakers and stakeholders across Europe, based on a shared understanding of the root causes of unavailability and access delays. This is a real opportunity to create a modernised system that can embrace the next generation of medicines and vaccines. Together, I hope we can achieve a healthier and stronger Europe. * https://lnkd.in/egnbJgvd #EFPIA #HealthPolicy #LifeSciences #HealthofEurope #MedicineAccess
The problem of equal access to treatment and manage by health systems arises in terms of territory and time. The economic evaluation of health products varies from one European country to another, today this is based on the sovereignty of European countries in terms of health budgets. Although regulatory frameworks such as the "European Network for Health Technology Assessment" (EUnetHTA) have been put in place to facilitate cooperation between European Union member countries in the assessment of health technologies, including medical products. There is a strong need to harmonize approaches and establish common guidelines to ensure consistent economic evaluation of health products across Europe before imagining a common health budget for all European countries!
Marta Diez
9mo
Congratulations Alexandre de Germay and thank you for representing Pfizer at the EFPIA Board, I am certain you will have a decisive role in improving access to healthcare to all Europeans
Congratulations Alexandre de Germay! We appreciate your leadership in Europe as we try to get more breakthroughs in to the hands of patients who need them most.
Christian Lenz
9mo
“Kudos, dear Alexandre, for your exemplary leadership across Europe. Your efforts are instrumental in delivering groundbreaking treatments to the European patients who need them the most.”
Great Leadership Alexandre de Germay ! Indeed, Europe needs to champion Innovation in #healthcare , both on R&D acceleration, #advancedtherapies, Direct to Patient Care, and also the necessary redesign of #suppychain, both upstream, downstream and clinical supply. Unique #challenge and #opportunity, for Europe.
Welcome back Alexandre de Germay!
Virginie Berel
9mo
Congratulations Alexandre. Fighting inequity of access is a critical mission for all pharma companies ; and it is so aligned with your personal values. It is great.
Congrats Alexandre! Great opportunity to create impact in an important common cause for the BioPharma industry.
Jeiran Otmishi
9mo
Congrats, Alexandre! What a brilliant opportunity to have a major impact 👍🏼👍🏼
Welcome to the Advanced Regulatory Global Network (ARGN), the epitome of regulatory excellence. Are you ready to transcend the conventional boundaries of compliance and join the forefront of regulatory innovation? ARGN offers an unparalleled platform where industry professionals, thought leaders, and innovators converge to shape the future of regulatory affairs on a global scale. Gain access to cutting-edge insights, connect with a diverse network of regulatory experts worldwide, and elevate your skills through specialized training programs and workshops. Join ARGN today and become a catalyst for positive change, influencing regulatory policies and standards across industries. Don't settle for ordinary—embrace the extraordinary with ARGN. https://shudarsana.com/community/